Skip Navigation



Carcinogenesis Advance Access published online on August 4, 2005

Carcinogenesis, doi:10.1093/carcin/bgi204
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow Supplementary Material
Right arrow All Versions of this Article:
27/1/84    most recent
bgi204v2
bgi204v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Khan, S. G.
Right arrow Articles by Kraemer, K. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khan, S. G.
Right arrow Articles by Kraemer, K. H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2005
Received June 7, 2005
Revised July 25, 2005
Accepted July 28, 2005

CANCER BIOLOGY

Reduced XPC DNA repair gene mRNA levels in clinically normal arents of xeroderma pigmentosum patients

Sikandar G. Khan 1, Kyu-Seon Oh 1, Tala Shahlavi 2, Takahiro Ueda 1, David B. Busch 3 {dagger}, Hiroki Inui 4, Steffen Emmert 5, Kyoko Imoto 1, Vanessa Muniz-Medina 6, Carl C. Baker 7, John J. DiGiovanna 8, Deborah Schmidt 1, Arash Khadavi 9, Ahmet Metin 10, Engin Gozukara 11, Hanoch Slor 12, Alain Sarasin 13, and Kenneth H. Kraemer 1*

1 Basic Research Laboratory, CCR, NCI, Bethesda, MD
2 Basic Research Laboratory, CCR, NCI, Bethesda, MD; Present Address: Washington and Lee Law School, Lexington, VA
3 Armed Forces Institute of Pathology, Washington, DC
4 Basic Research Laboratory, CCR, NCI, Bethesda, MD; Present Address: Kinki University School of Medicine, Osaka, Japan
5 Basic Research Laboratory, CCR, NCI, Bethesda, MD; Present Address: Georg-August-University, Goettingen, Germany (Partially supported by a grant from the Deutsche Forschungsgemeinschaft)
6 Laboratory of Cellular Oncology, CCR, NCI, Bethesda, MD; Present Address: University of North Carolina, Chapel Hill, NC
7 Laboratory of Cellular Oncology, CCR, NCI, Bethesda, MD
8 Basic Research Laboratory, CCR, NCI, Bethesda, MD; Department of Dermatology, Brown Medical School, Providence, R.I.
9 Basic Research Laboratory, CCR, NCI, Bethesda, MD; Present Address: University of California School of Medicine, Los Angeles, CA
10 Department of Dermatology, Yüzüncüyil University Medical School, Van, Turkey
11 Department of Biochemistry, Inönü University Medical School, Malatya, Turkey
12 Department of Human Genetics, Tel Aviv University Medical School, Tel Aviv, Israel
13 Laboratory of Genetic Instability and Cancer, UPR2169 CNRS, Institute Gustave Roussy, Villejuif, France

* To whom correspondence should be addressed.
Kenneth H. Kraemer, E-mail: kraemerk{at}nih.gov


   Abstract

Xeroderma pigmentosum group C (XP-C) is a rare autosomal recessive disorder. Patients with two mutant alleles of the XPC DNA repair gene have sun sensitivity and a 1000-fold increase in skin cancers. Clinically normal parents of XP-C patients have one mutant allele and one normal allele. As a step toward evaluating cancer risk in these XPC heterozygotes we characterized cells from 16 XP families. We identified 15 causative mutations (5 frameshift, 6 nonsense and 4 splicing) in the XPC gene in cells from 16 XP probands. All had premature termination codons (PTC) and absence of normal XPC protein on Western blotting. The cell lines from 26 parents were heterozygous for the same mutations. We employed a real-time quantitative reverse transcriptase-PCR (QRT-PCR) assay as a rapid and sensitive method to measure XPC mRNA levels. The mean XPC mRNA levels in the cell lines from the XP-C probands were 24% (p<10-7) of that in 10 normal controls. This reduced XPC mRNA in cells from XP-C patients was caused by the PTC that induces nonsense-mediated mRNA decay. The mean XPC mRNA levels in cell lines from the heterozygous XP-C carriers were intermediate (59%, p=10-4 ) between the values for the XP patients and the normal controls. This study demonstrates reduced XPC mRNA levels in XP-C patients and heterozygotes. Thus, XPC mRNA levels may be evaluated as a marker of cancer susceptibility in carriers of mutations in the XPC gene.


{dagger} Deceased


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
B. M. Bernardes de Jesus, M. Bjoras, F. Coin, and J. M. Egly
Dissection of the Molecular Defects Caused by Pathogenic Mutations in the DNA Repair Factor XPC
Mol. Cell. Biol., December 1, 2008; 28(23): 7225 - 7235.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
G. Yasuda, R. Nishi, E. Watanabe, T. Mori, S. Iwai, D. Orioli, M. Stefanini, F. Hanaoka, and K. Sugasawa
In Vivo Destabilization and Functional Defects of the Xeroderma Pigmentosum C Protein Caused by a Pathogenic Missense Mutation
Mol. Cell. Biol., October 1, 2007; 27(19): 6606 - 6614.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.